CNS Drugs,
Год журнала:
2023,
Номер
37(7), С. 599 - 637
Опубликована: Июнь 21, 2023
Even
though
language
is
essential
in
human
communication,
research
on
pharmacological
therapies
for
deficits
highly
prevalent
neurodegenerative
and
vascular
brain
diseases
has
received
little
attention.
Emerging
scientific
evidence
suggests
that
disruption
of
the
cholinergic
system
may
play
an
role
associated
with
Alzheimer's
disease
cognitive
impairment,
including
post-stroke
aphasia.
Therefore,
current
models
processing
are
beginning
to
appraise
implications
modulator
acetylcholine
functions.
Future
work
should
be
directed
further
analyze
interplay
between
language,
focusing
identifying
regions
receiving
innervation
susceptible
modulation
pharmacotherapy
improve
affected
domains.
The
evaluation
trials
impairment
thus
far
been
limited
coarse-grained
methods.
More
precise,
fine-grained
testing
needed
refine
patient
selection
detect
subtle
initial
phases
decline.
Additionally,
noninvasive
biomarkers
can
help
identify
depletion.
However,
despite
investigation
treatment
data
its
effectiveness
insufficient
controversial.
In
case
aphasia,
agents
showing
promise,
particularly
when
combined
speech-language
therapy
promote
trained-dependent
neural
plasticity.
explore
potential
benefits
investigate
optimal
strategies
combining
these
other
therapeutic
approaches.
PLoS ONE,
Год журнала:
2025,
Номер
20(5), С. e0320789 - e0320789
Опубликована: Май 20, 2025
Alzheimer’s
disease
(AD)
causes
a
progressive
decline
in
memory,
along
with
impairments
other
cognitive
abilities.
The
main
pharmacological
target
for
treatment
is
acetylcholinesterase
(AChE),
biochemical
enzyme
belonging
to
the
cholinesterase
(ChE)
family.
In
search
novel
hit
compoundswith
potential
as
future
Alzheimer's
therapies,
series
of
carbamates
derivatives
were
designed
and
evaluated
using
computational
approaches
including
QSAR
modeling,
molecular
docking,
ADMET
profiling,
dynamics
simulations.
following
study
focused
on
development
model
satisfactory
statistical
properties.
analysis
ligands,
demonstrated
good
pharmacokinetic
Molecular
docking
identified
M6
promising
AChE
binder
score
-11.200
kcal/mol,
while
Donepezil
control
returned
-10.800
kcal/mol.
validity
docked
complex
was
confirmed
simulations,
where
trajectory
plots
found
be
stable
consistent
over
100
ns
intervals.
enclosed
highlights
chemical
starting
point
(CSP)
(i.e.,
compound)
targeting
therapeutic
strategy
against
AD.
Heliyon,
Год журнала:
2024,
Номер
10(9), С. e30523 - e30523
Опубликована: Апрель 30, 2024
Alzheimer's
disease
(AD)
is
a
common
neurodegenerative
in
the
elderly,
exact
pathogenesis
of
which
remains
incompletely
understood,
and
effective
preventive
therapeutic
drugs
are
currently
lacking.
Cholesterol
plays
vital
role
cell
membrane
formation
neurotransmitter
synthesis,
its
abnormal
metabolism
associated
with
onset
AD.
With
continuous
advancement
imaging
techniques
molecular
biology
methods,
researchers
can
more
accurately
explore
relationship
between
cholesterol
Elevated
levels
may
lead
to
vascular
dysfunction,
thereby
affecting
neuronal
function.
Additionally,
affect
β-amyloid
protein,
promoting
Brain
regulated
by
multiple
factors.
This
review
aims
deepen
understanding
subtle
homeostasis
AD,
introduce
latest
advances
cholesterol-regulating
AD
treatment
strategies,
inspiring
readers
contemplate
deeply
on
this
complex
relationship.
Although
there
still
many
unresolved
important
issues
regarding
risk
brain
some
studies
have
opposite
conclusions,
further
research
needed
enrich
our
understanding.
However,
these
findings
expected
provide
insights
for
future
development
strategies
targeting
homeostasis.
CNS Drugs,
Год журнала:
2023,
Номер
37(7), С. 599 - 637
Опубликована: Июнь 21, 2023
Even
though
language
is
essential
in
human
communication,
research
on
pharmacological
therapies
for
deficits
highly
prevalent
neurodegenerative
and
vascular
brain
diseases
has
received
little
attention.
Emerging
scientific
evidence
suggests
that
disruption
of
the
cholinergic
system
may
play
an
role
associated
with
Alzheimer's
disease
cognitive
impairment,
including
post-stroke
aphasia.
Therefore,
current
models
processing
are
beginning
to
appraise
implications
modulator
acetylcholine
functions.
Future
work
should
be
directed
further
analyze
interplay
between
language,
focusing
identifying
regions
receiving
innervation
susceptible
modulation
pharmacotherapy
improve
affected
domains.
The
evaluation
trials
impairment
thus
far
been
limited
coarse-grained
methods.
More
precise,
fine-grained
testing
needed
refine
patient
selection
detect
subtle
initial
phases
decline.
Additionally,
noninvasive
biomarkers
can
help
identify
depletion.
However,
despite
investigation
treatment
data
its
effectiveness
insufficient
controversial.
In
case
aphasia,
agents
showing
promise,
particularly
when
combined
speech-language
therapy
promote
trained-dependent
neural
plasticity.
explore
potential
benefits
investigate
optimal
strategies
combining
these
other
therapeutic
approaches.
